Accessibility Menu

Lakewood-Amedex Biotherapeutics

(NASDAQ) LABT

Current Price$0.64
Market Cap$4.67M
Since IPO (2026)-92%
5 YearN/A
1 YearN/A
1 Month-79%

Lakewood-Amedex Biotherapeutics Financials at a Glance

Market Cap

$4.67M

Revenue (TTM)

$0.00

Net Income (TTM)

-$4.23

EPS (TTM)

-$0.88

P/E Ratio

-0.76

Dividend

$0.00

Beta (Volatility)

5.87 (High)

Price

$0.64

Volume

355,476.186

Open

$0.70

Previous Close

$0.67

Daily Range

$0.62 - $0.71

52-Week Range

$0.59 - $9.82

Estimated Earnings Date

N/A

LABT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Lakewood-Amedex Biotherapeutics

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Kelvin Cooper, PhD

Website

www.lakewoodamedex.com

Headquarters

University Park, FL 34201, US

LABT Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-1.32%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$4.67M

Shares Outstanding

7.00M

Volume

355.48K

Avg. Volume

3.20M

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Lakewood-Amedex Biotherapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.67M

N/A

Market Cap/Employee

$934.60K

N/A

Employees

5

N/A

Net Income

-$923.29K

N/A

EBITDA

-$886.19K

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Net Cash

-$1.74M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$10.30K

N/A

Short Term Debt

$1.75M

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$349.69K

N/A

Operating Cash Flow

-$349.69K

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,383.74-0.03%
^DJIDJI
$50,866.78-0.01%
^IXICNASDAQ
$25,709.43-0.04%
BTCBitcoin
$62,143.00+0.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$14.38-0.13%
TQQQProShares Trust - ProShares UltraPro Qqq
$73.05-0.14%
KEELKeel Infrastructure
$5.13-0.13%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$43.19+0.14%

Questions About LABT

What is the current price of Lakewood-Amedex Biotherapeutics?

Lakewood-Amedex Biotherapeutics is trading at $0.67 per share.

What is the 52-week range for Lakewood-Amedex Biotherapeutics?

Over the past 52 weeks, Lakewood-Amedex Biotherapeutics has traded between $0.59 and $9.82.

How much debt does Lakewood-Amedex Biotherapeutics have?

As of the most recent reporting period, Lakewood-Amedex Biotherapeutics reported total debt of $1.76M.

How much cash does Lakewood-Amedex Biotherapeutics have on hand?

Lakewood-Amedex Biotherapeutics reported $11.71K in cash and cash equivalents in its most recent financial results.

What is Lakewood-Amedex Biotherapeutics’s dividend yield?

Lakewood-Amedex Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services